Apricus Biosciences, Inc (NASDAQ:APRI) – Investment analysts at Seethru Equity issued their FY2017 earnings per share (EPS) estimates for shares of Apricus Biosciences in a research note issued on Tuesday. Seethru Equity analyst A. Tandon forecasts that the company will earn ($0.28) per share for the year.
Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Apricus Biosciences from a “buy” rating to a “sell” rating in a research report on Tuesday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $4.50 price objective on shares of Apricus Biosciences in a research report on Friday, November 3rd.
ILLEGAL ACTIVITY WARNING: “Apricus Biosciences, Inc to Post FY2017 Earnings of ($0.28) Per Share, Seethru Equity Forecasts (APRI)” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/12/apricus-biosciences-inc-to-post-fy2017-earnings-of-0-28-per-share-seethru-equity-forecasts-apri.html.
Apricus Biosciences (APRI) opened at $1.58 on Friday. Apricus Biosciences has a 52 week low of $0.86 and a 52 week high of $4.07.
Apricus Biosciences (NASDAQ:APRI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.15). During the same period in the previous year, the business posted ($0.19) EPS.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.